Ironwood Pharmaceuticals Inc. (IRWD)
Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating
The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works, sending the stock to the moon, or it fails, causing a crash.
5 Small Drug Stocks to Buy as Industry Recovery Picks Up
Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.
Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026
IRWD shares jump on upbeat 2026 revenue guidance amid rising Linzess demand in the United States. The company also provides a key pipeline update.
Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report?
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?
Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.
Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025
Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk.
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?
Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.
IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?
Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.
IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars
Ironwood posts a stellar third-quarter beat with higher revenues and raises 2025 outlook on Linzess-driven strength.
Ironwood Pharmaceuticals (IRWD) Q3 Earnings and Revenues Surpass Estimates
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.02 per share a year ago.
Why Ironwood Pharmaceuticals (IRWD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IRWD Stock Rises as Q2 Earnings & Revenues Trump Estimates
Ironwood shares jump 9.3% as second-quarter earnings and revenues top estimates. The company maintains its 2025 outlook.
